Fulgent Genetics Inc (FLGT)vsNovartis AG ADR (NVS)
FLGT
Fulgent Genetics Inc
$19.64
+0.05%
HEALTHCARE · Cap: $558.64M
NVS
Novartis AG ADR
$158.83
-0.24%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 17597% more annual revenue ($56.69B vs $320.35M). NVS leads profitability with a 22.5% profit margin vs -23.0%. FLGT appears more attractively valued with a PEG of 1.32. NVS earns a higher WallStSmart Score of 51/100 (C-).
FLGT
Hold40
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.9%
Fair Value
$49.90
Current Price
$19.64
$30.26 discount
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -7.0% — below average capital efficiency
Revenue declined 3.2%
Earnings declined 98.6%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : FLGT
The strongest argument for FLGT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : FLGT
The primary concerns for FLGT are Market Cap, Return on Equity, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
FLGT profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
FLGT carries more volatility with a beta of 0.89 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 22.5% margins. FLGT offers better value entry with a 53.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fulgent Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?